| Therapeutic options for mucopolysaccharidoses: current and emerging treatments K Sawamoto, M Stapleton, CJ Alméciga-Díaz, AJ Espejo-Mojica, ... Drugs 79 (10), 1103-1134, 2019 | 83 | 2019 |
| GM2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies AF Leal, E Benincore-Flórez, D Solano-Galarza, RG Garzón Jaramillo, ... International journal of molecular sciences 21 (17), 6213, 2020 | 78 | 2020 |
| Delivery and assessment of a CRISPR/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles AF Leal, J Cifuentes, CE Torres, D Suárez, V Quezada, SC Gómez, ... Scientific Reports 12 (1), 15045, 2022 | 8 | 2022 |
| A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia MA Puentes-Tellez, PA Lerma-Barbosa, RG Garzón-Jaramillo, DA Suarez, ... Heliyon 6 (3), 2020 | 8 | 2020 |
| Sphingolipids and their role in health and disease in the central nervous system AF Leal, DA Suarez, OY Echeverri-Peña, SL Albarracín, ... Advances in Biological Regulation 85, 100900, 2022 | 6 | 2022 |
| Evaluation of lentiviral vectors in Morquio syndrome type A patients' fibroblasts A Puentes-Tellez, F Rojas-Rodríguez, D Suarez, OA Hidalgo, ... Molecular Genetics and Metabolism 126 (2), S120, 2019 | 2 | 2019 |
| GM2 gangliosidosis insights: Tay-Sachs models via CRISPR-Cas9 D Suarez, AJ Espejo, CJ Alméciga-Díaz Molecular Genetics and Metabolism 141 (2), 108052, 2024 | | 2024 |
| Treatment with recombinant human lysosomal β-hexosaminidase reduces GM2 accumulation in Tay-Sachs disease cells OK Inci, AF Leal, N Ates, D Suarez, AJ Espejo, CJ Alméciga-Díaz, ... Molecular Genetics and Metabolism 141 (2), 107896, 2024 | | 2024 |
| Initial characterization of cellular models for mucopolysaccharidosis type IIIB generated by CRISPR/Cas9 K Niño, D Suarez, AJ Espejo, CJ Alméciga-Díaz Molecular Genetics and Metabolism 141 (2), 107982, 2024 | | 2024 |
| Genome Editing Tools for Lysosomal Storage Disorders EA Gonzalez, H Nader, M Siebert, DA Suarez, CJ Alméciga-Díaz, G Baldo Genome Editing in Biomedical Sciences, 127-155, 2023 | | 2023 |
| Molecular Trojan Horses for treating lysosomal storage diseases AF Leal, OK Inci, V Seyrantepe, E Rintz, B Celik, Y Ago, D León, ... Molecular Genetics and Metabolism, 107648, 2023 | | 2023 |
| Pharmacological chaperones as an alternative to increase GALNS activity in mucopolysaccharidosis type IVA L Prada, DA Suárez, CJ Alméciga-Díaz Molecular Genetics and Metabolism 138 (2), 107276, 2023 | | 2023 |
| Magnetoliposomes as Carriers for CRISPR/nCas9-Based Gene Therapy on In Vitro Models of Mucopolysaccharidoses IVA and GM2 Gangliosidoses: Proof-of-Concept Experiments AF Leal, D Suarez, V Quezada, CE Torres, SC Gomez, J Espejo-Mojica, ... MOLECULAR THERAPY 30 (4), 475-476, 2022 | | 2022 |
| Genome editing in mucopolysaccharidosis type IVA fibroblasts using CRISPR/Cas9 DA Suarez, CJ Almeciga Molecular Genetics and Metabolism 135 (2), S117, 2022 | | 2022 |
| Sphingolipids and cell signaling: Relationship between health and disease in the central nervous system AF Leal, DA Suarez, OY Echeverri-Peña, SL Albarracín, ... Preprints, 2021 | | 2021 |
| A perspective on research, diagnosis, and management of lysosomal disorders in Colombia: An update MA Puentes-Tellez, PA Lerma-Barbosa, RG Garzón-Jaramillo, D Suarez, ... Molecular Genetics and Metabolism 132 (2), S88, 2021 | | 2021 |
